ScinoPharm Taiwan Salute del bilancio

Salute finanziaria criteri di controllo 6/6

ScinoPharm Taiwan ha un patrimonio netto totale di NT$10.4B e un debito totale di NT$8.9M, che porta il suo rapporto debito/patrimonio netto a 0.09%. Le sue attività totali e le sue passività totali sono rispettivamente NT$12.0B e NT$1.6B. L'EBIT di ScinoPharm Taiwan è NT$442.1M rendendo il suo rapporto di copertura degli interessi -9.1. Ha liquidità e investimenti a breve termine pari a NT$4.2B.

Informazioni chiave

0.09%

Rapporto debito/patrimonio netto

NT$8.87m

Debito

Indice di copertura degli interessi	-9.1x
Contanti	NT$4.21b
Patrimonio netto	NT$10.37b
Totale passività	NT$1.62b
Totale attività	NT$12.00b

Aggiornamenti recenti sulla salute finanziaria

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NT$6.7B ) di 1789 superano le sue passività a breve termine ( NT$972.5M ).

Passività a lungo termine: Le attività a breve termine di 1789 ( NT$6.7B ) superano le sue passività a lungo termine ( NT$651.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 1789 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 1789 si è ridotto da 13.1% a 0.09% negli ultimi 5 anni.

Copertura del debito: Il debito di 1789 è ben coperto dal flusso di cassa operativo ( 6816.6% ).

Copertura degli interessi: 1789 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

ScinoPharm Taiwan Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Recent updates

ScinoPharm Taiwan, Ltd. to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.072 in 2Q 2023)

ScinoPharm Taiwan, Ltd. to Report Q2, 2024 Results on Aug 05, 2024

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Dividend reduced to NT$0.30

New minor risk - Earnings quality

Scinopharm Taiwan, Ltd. Elects Lai-Shou Su as Independent Director

First quarter 2024 earnings released: EPS: NT$0.18 (vs NT$0.053 in 1Q 2023)

ScinoPharm Taiwan, Ltd. to Report Q1, 2024 Results on May 06, 2024

Now 22% undervalued

Now 20% undervalued

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 28, 2024

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: NT$0.07 (vs NT$0.14 in 2Q 2022)

Upcoming dividend of NT$0.36 per share at 1.2% yield

ScinoPharm Taiwan, Ltd. Approves Cash Dividend for 2022, Payable on July 28, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$0.48 per share

Consensus EPS estimates increase by 13%

Scinopharm Taiwan, Ltd Approves Cash Dividend, Payable August 2, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ScinoPharm Taiwan, Ltd Announces Executive Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 30, 2022

Third quarter 2021 earnings released: EPS NT$0.01 (vs NT$0.097 in 3Q 2020)

Upcoming dividend of NT$0.50 per share

Second quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.20 in 2Q 2020)

Consensus EPS estimates increase to NT$0.61

First quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.045 in 1Q 2020)

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Full year 2020 earnings released: EPS NT$0.36 (vs NT$0.27 in FY 2019)

ScinoPharm Taiwan, Ltd., Annual General Meeting, Jun 29, 2021

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

New 90-day low: NT$24.15

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

New 90-day low: NT$27.00

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

New 90-day low: NT$27.95

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Revenue and earnings miss expectations

Third quarter 2020 earnings released: EPS NT$0.10

New 90-day low: NT$29.40

Second-quarter earnings released: Revenue and earnings beat expectations

First half earnings released

New 90-day low: NT$30.15

First half earnings released

Upcoming Dividend of NT$0.27 Per Share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane